Compassionate Use of Ubamatamab
NCT07502716 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-03-31
Summary
Provide Compassionate Use of Ubamatamab
Conditions
- Renal Medullary Carcinoma (RMC)
- Epithelioid Sarcoma
Interventions
- DRUG
-
ubamatamab
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
NCT05048212 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
NCT04489771 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
NCT00515697 ·Status: COMPLETED ·Phase: PHASE2
-
Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer
NCT03867045 ·Status: TERMINATED ·Phase: NA
-
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
NCT00112671 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma
NCT04501094 ·Status: TERMINATED ·Phase: PHASE2
-
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
NCT00184015 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
NCT03200587 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
NCT00265135 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
NCT00445042 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
NCT00112905 ·Status: TERMINATED ·Phase: PHASE2
-
A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
NCT00059735 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00496756 ·Status: TERMINATED ·Phase: PHASE2
-
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
NCT01472081 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
NCT02459119 ·Status: COMPLETED ·Phase: PHASE2
-
Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium
NCT01551030 ·Status: COMPLETED ·Phase: PHASE2
-
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
NCT07037004 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
R115777 in Treating Patients With Advanced Bladder Cancer
NCT00006376 ·Status: COMPLETED ·Phase: PHASE2
-
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
NCT00047216 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib and RAD001 Renal Cell Carcinoma
NCT00384969 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
NCT01182142 ·Status: COMPLETED ·Phase: PHASE2
-
SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment
NCT00009919 ·Status: TERMINATED ·Phase: PHASE2
-
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
NCT02596035 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
NCT07179770 ·Status: RECRUITING ·Phase: PHASE1
-
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
NCT07470840 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2